Centivax, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Centivax is a clinical stage company that leverages our computational bioengineering platforms to solve drugability and manufacturability problems of validated but challenging drug targets. Most of our targets are complex because of mutation diversity. Our broad therapeutic portfolio of two clinical stage and thirteen pre-clinical programs includes broad-spectrum vaccines and broadly neutralizing antibodies against rapidly mutating viruses such as SARS-CoV-2, and influenza; diverse and multi-drug resistant bacteria such as MRSA, Klebsiella, and Pseudomonas; highly mutable cancers and immune-oncology targets; auto-immune disorder targets; and the complex cocktail of toxins found in snake venom.

Our unfair advantage is our intellectual property and engineering expertise in broad spectrum vaccines and broadly neutralizing antibodies that can confront these highly diverse targets, and delivered through both vaccines and antibodies that can be administered through convenient injection.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
COVID-19 injectable therapeutic effective against novel mutant strains
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
15
Speaker
photo
Founder/CEO/President
Centivax, Inc.